SAB Biotherapeutics, Inc. Common Stock

$3.428
USD
Last updated on --.
24h volume8.91K
24h highest3.4050 USD
24h lowest3.4050 USD
24h Price movement+0.53%

SABS recent prices

24 Hours
+0.53%+$0.018
30 days
-9.68%-$0.365
60 days
-1.98%-$0.07
90 days
-14.88%-$0.595

Key data

Previous close3.4100 USD
Market cap310.26M USD
Volume8.91K
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)-0.43000 USD
Net income (FY)-12.78M USD
Revenue (FY)0.00 USD
Last report dateAug 6, 2026

About SAB Biotherapeutics, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
HeadquartersMIAMI BEACH
Employees (FY)86.00
Revenue per employee (FY)0.00 USD
Net income per employee (FY)-148.55K USD
Listed onNasdaq
Official website

SABS conversion tables

SABSSABS
USDUSD
0.5 SABS1.714 USD
1 SABS3.428 USD
5 SABS17.14 USD
10 SABS34.28 USD
USDUSD
SABSSABS
0.5 USD0.14586 SABS
1 USD0.29172 SABS
5 USD1.458 SABS
10 USD2.917 SABS

FAQ

SABS is trading at $3.428, +0.53% over the last 24 hours. Track live moves on the price chart at the top of this page.
The SABS stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. SABS is currently trading at $3.428, +0.53% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on SABS price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. SABS's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from SABS; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against SABS's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
SAB Biotherapeutics, Inc. Common Stock's market cap is currently 310.26M USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume8.91K
24h highest3.4050 USD
24h lowest3.4050 USD
24h Price movement+0.53%
SABSSABS
USDUSD
Start trade with SABS Perpetual